[go: up one dir, main page]

MX2017011279A - Metodo de tratamiento con tradipitant. - Google Patents

Metodo de tratamiento con tradipitant.

Info

Publication number
MX2017011279A
MX2017011279A MX2017011279A MX2017011279A MX2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A MX 2017011279 A MX2017011279 A MX 2017011279A
Authority
MX
Mexico
Prior art keywords
tradipitant
treatment method
treatment
pruritus
application relates
Prior art date
Application number
MX2017011279A
Other languages
English (en)
Other versions
MX385788B (es
Inventor
Louis William Licamele
H Polymeropoulos Mihael
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2017011279A publication Critical patent/MX2017011279A/es
Publication of MX385788B publication Critical patent/MX385788B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La solicitud se refiere a un método de tratamiento con tradipitant, y, más particularmente, a un método de tratamiento de prurito con tradipitant.
MX2017011279A 2015-03-04 2016-03-04 Método de tratamiento con tradipitant. MX385788B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US201562232644P 2015-09-25 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Publications (2)

Publication Number Publication Date
MX2017011279A true MX2017011279A (es) 2018-01-25
MX385788B MX385788B (es) 2025-03-18

Family

ID=55629110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017011279A MX385788B (es) 2015-03-04 2016-03-04 Método de tratamiento con tradipitant.
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010460A MX2021010460A (es) 2015-03-04 2017-09-04 Metodo de tratamiento con tradipitant.

Country Status (19)

Country Link
US (6) US10463655B2 (es)
EP (2) EP3730140A1 (es)
JP (4) JP6891385B2 (es)
KR (3) KR102860817B1 (es)
CN (2) CN113262221A (es)
AU (4) AU2016226006B2 (es)
BR (1) BR112017018620A2 (es)
CA (2) CA3213864A1 (es)
CL (1) CL2017002238A1 (es)
DK (1) DK3265087T3 (es)
ES (1) ES2824552T3 (es)
HR (1) HRP20201627T1 (es)
HU (1) HUE050944T2 (es)
IL (1) IL254142B (es)
MX (2) MX385788B (es)
PT (1) PT3265087T (es)
RU (1) RU2770050C2 (es)
WO (1) WO2016141341A1 (es)
ZA (1) ZA201706059B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20200054232A (ko) * 2017-09-13 2020-05-19 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
IL274541B2 (en) * 2017-11-17 2024-10-01 Vanda Pharmaceuticals Inc Method of treatment of gastrointestinal diseases with tradipitant
WO2019236852A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
FI3856338T3 (fi) * 2018-09-28 2025-02-03 Vanda Pharmaceuticals Inc Tradipitantin käyttö matkapahoinvoinnissa
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
IL295327A (en) * 2020-02-25 2022-10-01 Vanda Pharmaceuticals Inc Improved treatment of atopic dermatitis with tradipitant
EP4125811A1 (en) 2020-03-26 2023-02-08 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
WO2003091226A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
CN1313450C (zh) * 2002-04-26 2007-05-02 伊莱利利公司 速激肽受体拮抗剂
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ATE462700T1 (de) * 2003-10-24 2010-04-15 Lilly Co Eli Neue kristalline formen von ä2-ä1-(3,5- bistrifluormethylbenzyl)-5-pyridin-4-yl-1h-ä1,2 3üütriazol-4-ylü-pyridin-3-ylü-(2- chlorphenyl)methanon
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
EP1996179A2 (en) 2006-02-22 2008-12-03 Valorisation-Recherche, Limited Partnership Compositions for disorders associated with metachromatic cell activation
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
ES2609640T3 (es) 2009-08-14 2017-04-21 Opko Health, Inc Formulaciones intravenosas de rolapitant
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2014093907A1 (en) 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
MX366728B (es) * 2013-06-24 2019-07-22 Menlo Therapeutics Inc Uso de serlopitant como antagonistas del receptor nk-1 en prurito.
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
KR20200054232A (ko) * 2017-09-13 2020-05-19 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
IL274541B2 (en) * 2017-11-17 2024-10-01 Vanda Pharmaceuticals Inc Method of treatment of gastrointestinal diseases with tradipitant
WO2019236852A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
FI3856338T3 (fi) * 2018-09-28 2025-02-03 Vanda Pharmaceuticals Inc Tradipitantin käyttö matkapahoinvoinnissa
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Also Published As

Publication number Publication date
MX385788B (es) 2025-03-18
PT3265087T (pt) 2020-10-15
US10772880B2 (en) 2020-09-15
AU2016226006A1 (en) 2017-09-21
CN113262221A (zh) 2021-08-17
AU2023233141A1 (en) 2023-10-12
KR102860817B1 (ko) 2025-09-16
WO2016141341A1 (en) 2016-09-09
CN107427502B (zh) 2021-06-04
AU2021202956A1 (en) 2021-06-03
US10463655B2 (en) 2019-11-05
IL254142B (en) 2022-05-01
US20190290626A1 (en) 2019-09-26
CA2978736C (en) 2023-11-07
CL2017002238A1 (es) 2018-04-20
JP6891385B2 (ja) 2021-06-18
MX2021010460A (es) 2021-09-21
JP2023052486A (ja) 2023-04-11
EP3730140A1 (en) 2020-10-28
US20220226295A1 (en) 2022-07-21
AU2016226006B2 (en) 2021-03-04
RU2017134443A (ru) 2019-04-04
BR112017018620A2 (pt) 2018-04-17
HRP20201627T1 (hr) 2021-02-19
HK1248552A1 (zh) 2018-10-19
JP2024074963A (ja) 2024-05-31
EP3265087B1 (en) 2020-07-22
AU2021202956B2 (en) 2023-06-29
KR20170122777A (ko) 2017-11-06
EP3265087A1 (en) 2018-01-10
CA3213864A1 (en) 2016-09-09
US20250205213A1 (en) 2025-06-26
US11324735B2 (en) 2022-05-10
AU2023233141B2 (en) 2025-05-22
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
CN107427502A (zh) 2017-12-01
CA2978736A1 (en) 2016-09-09
RU2770050C2 (ru) 2022-04-14
JP2021073258A (ja) 2021-05-13
ZA201706059B (en) 2023-08-30
ES2824552T3 (es) 2021-05-12
JP2018507243A (ja) 2018-03-15
AU2025210905A1 (en) 2025-08-21
US20180110761A1 (en) 2018-04-26
US20200360358A1 (en) 2020-11-19
KR20250136946A (ko) 2025-09-16
NZ735121A (en) 2024-07-26
KR20230173743A (ko) 2023-12-27
US20190290625A1 (en) 2019-09-26
US12318375B2 (en) 2025-06-03
RU2017134443A3 (es) 2019-09-05
IL254142A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201691991A1 (ru) Мультиспецифические антитела
MX377710B (es) Anticuerpos monoclonales contra bcma.
EA201792613A1 (ru) Модуляторы cot и способы их применения
MX370807B (es) Anticuerpos que se unen a axl.
PH12017500019A1 (en) Novel ultra-high performance concrete
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PL3250042T3 (pl) Kompozycja, sposób, zastosowanie i wyrób
BR112016027455A2 (pt) moduladores ppar
EA201792527A1 (ru) Лечение зуда
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
EP3463579A4 (en) CALLYSPONGIOLID, ANALOGUE FROM IT AND USES THEREOF
EA201792578A1 (ru) Многослойная сборка
LT3493849T (lt) N,n-bis-2-merkaptoetilizoftalamido naujas panaudojimas
RU2014119029A (ru) Способ остеопластической торакопластики из минидоступа
TN2014000384A1 (fr) نظام صوتي ذكي وآمن
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
UA114708U (uk) Тяговий привід електробуса
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت
TN2014000522A1 (fr) لوح مدرسي بوجهين
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin
TH1601003420A (th) วิธีการผลิตของ 1,3-บิวทาไดอีน